CO6950477A2 - Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes - Google Patents

Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes

Info

Publication number
CO6950477A2
CO6950477A2 CO14097119A CO14097119A CO6950477A2 CO 6950477 A2 CO6950477 A2 CO 6950477A2 CO 14097119 A CO14097119 A CO 14097119A CO 14097119 A CO14097119 A CO 14097119A CO 6950477 A2 CO6950477 A2 CO 6950477A2
Authority
CO
Colombia
Prior art keywords
autoimmune
treat cancer
immune diseases
inducing agents
apoptosis inducing
Prior art date
Application number
CO14097119A
Other languages
English (en)
Inventor
Le Wang
George Doherty
Xilu Wang
Zhi-Fu Tao
Milan Brunko
Aaron R Kunzer
Michael D Wendt
Xiaohong Song
Robin Frey
Todd M Hansen
Gerard M Sullivan
Andrew Judd
Andrew Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CO6950477A2 publication Critical patent/CO6950477A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos que inhiben la actividad de las proteínas antiapoptóticas Bcl-xL, composiciones que contienen dichos compuestos y métodos para tratar enfermedades en las que se expresan las proteínas antiapoptóticas Bcl-xL.
CO14097119A 2011-10-14 2014-05-07 Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes CO6950477A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547165P 2011-10-14 2011-10-14
CN2012078372 2012-07-09

Publications (1)

Publication Number Publication Date
CO6950477A2 true CO6950477A2 (es) 2014-05-20

Family

ID=47073545

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14097119A CO6950477A2 (es) 2011-10-14 2014-05-07 Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes

Country Status (22)

Country Link
EP (2) EP3266776A1 (es)
JP (2) JP6049738B2 (es)
KR (1) KR102056587B1 (es)
CN (1) CN109535155B (es)
AR (1) AR088328A1 (es)
AU (2) AU2012322818A1 (es)
BR (1) BR112014009052B1 (es)
CA (1) CA2850976C (es)
CL (1) CL2014000922A1 (es)
CO (1) CO6950477A2 (es)
DO (1) DOP2014000074A (es)
EC (1) ECSP14000606A (es)
ES (1) ES2699966T3 (es)
IL (1) IL231926A (es)
MX (2) MX351970B (es)
PE (2) PE20181357A1 (es)
RU (1) RU2594282C2 (es)
SG (2) SG10201606031XA (es)
TW (1) TWI561521B (es)
UY (1) UY34381A (es)
WO (1) WO2013055895A1 (es)
ZA (1) ZA201402555B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN111620862A (zh) * 2014-12-09 2020-09-04 艾伯维公司 Bcl-xl抑制性化合物和包括其的抗体药物缀合物
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EP3952853A4 (en) * 2019-04-12 2023-04-12 Tonix Pharmaceuticals Holding Corp. INHIBITORS OF CD40-CD154 BINDING
KR102316961B1 (ko) * 2020-01-29 2021-10-26 프라비바이오 주식회사 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
WO2022115477A1 (en) 2020-11-24 2022-06-02 Novartis Ag Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CA3206906A1 (en) 2021-02-02 2022-08-11 Andras Herner Selective bcl-xl protac compounds and methods of use
TW202404645A (zh) 2022-05-20 2024-02-01 瑞士商諾華公司 Met bcl-xl抑制劑抗體-藥物結合物及其使用方法
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
RU2388751C2 (ru) * 2004-07-15 2010-05-10 Амр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
EP2148867B1 (en) 2007-04-19 2014-09-10 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
AU2009335843A1 (en) * 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
MX2011006514A (es) * 2008-12-19 2011-10-11 Inst Medical W & E Hall Compuesto y metodo de uso.
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑

Also Published As

Publication number Publication date
PE20181357A1 (es) 2018-08-22
RU2594282C2 (ru) 2016-08-10
CN109535155A (zh) 2019-03-29
JP6049738B2 (ja) 2016-12-21
RU2014119254A (ru) 2015-11-20
SG11201401479SA (en) 2014-07-30
KR102056587B1 (ko) 2019-12-18
SG10201606031XA (en) 2016-09-29
AU2012322818A1 (en) 2014-04-17
PE20141997A1 (es) 2015-01-07
BR112014009052B1 (pt) 2022-01-04
MX351970B (es) 2017-11-06
AR088328A1 (es) 2014-05-28
NZ623068A (en) 2016-07-29
ECSP14000606A (es) 2015-06-30
MX364950B (es) 2019-05-15
ES2699966T3 (es) 2019-02-13
CN109535155B (zh) 2022-07-12
TW201319065A (zh) 2013-05-16
IL231926A (en) 2016-11-30
JP2014530237A (ja) 2014-11-17
BR112014009052A2 (pt) 2017-06-13
ZA201402555B (en) 2019-10-30
CA2850976A1 (en) 2013-04-18
IL231926A0 (en) 2014-05-28
JP2017061535A (ja) 2017-03-30
UY34381A (es) 2013-05-31
TWI561521B (en) 2016-12-11
KR20140084174A (ko) 2014-07-04
EP2768830B1 (en) 2018-08-29
DOP2014000074A (es) 2014-07-15
JP6337068B2 (ja) 2018-06-06
EP2768830A1 (en) 2014-08-27
MX2014004561A (es) 2014-11-14
EP3266776A1 (en) 2018-01-10
AU2017206149B2 (en) 2018-11-08
CL2014000922A1 (es) 2014-08-18
CA2850976C (en) 2020-03-10
AU2017206149A1 (en) 2017-08-03
WO2013055895A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CO6950476A2 (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
DOP2016000100A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
CO6640274A2 (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
BR112012024382A2 (pt) agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
CO6940433A2 (es) Compuestos inhibidores de metaloenzimas
ECSP14030779A (es) Inhibidores del nampt
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
CR20130267A (es) Inhibidores de nampt y rock
UA106640C2 (uk) Bcl-2-СЕЛЕКТИВНИЙ АПОПТОЗІНДУКУЮЧИЙ ЗАСІБ ДЛЯ ЛІКУВАННЯ РАКУ І ІМУННИХ ЗАХВОРЮВАНЬ
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
UY34479A (es) Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales
CU20120052A7 (es) Derivados de pirazol que modulan estearoil-coa-desaturasa